A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Inclusion Criteria: * Adequate complete blood counts, liver and renal function * Female subjects must be of non-childbearing potential; e.g. post-menopausal or pre-menopausal with surgical sterilization * Male subjects agree to use appropriate contraception * Willing to provide written informed consent and willing to comply with study requirements. * Non-smokers and non-nicotine users for at least 90 days before screening * On stable statin co-medication \[for designated multiple dose cohorts only\] Exclusion Criteria: * Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk * Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study * History of multiple drug allergies or intolerance to subcutaneous injection * Received any medication or nutraceutical to alter serum lipids within 30 days before screening (non-statin cohorts only)